Establishing Latin America's Premier Theranostics Center at Fundación Cardioinfantil – LaCardio
A strategic partnership to secure generational leadership in personalized medicine, combining diagnostics and targeted therapies to transform patient care in Latin America.
View Full Proposal
The Integral Theranostics Proposal
This proposal outlines a strategic alliance among three pivotal Latin American entities, combining clinical excellence, academic leadership, and innovative theranostics solutions to transform patient care.
Fundación Cardioinfantil – LaCardio
Colombia's premier clinical reference in cardiovascular care, transplants, and high complexity, with international accreditation and a patient-centered model.
Universidad El Bosque
A recognized academic leader, focusing on applied research, bioethics, and interdisciplinary health professional training with modern infrastructure.
The Synapse Latam Partnership
Specializes in comprehensive nuclear medicine and theranostics, offering a proven "turnkey" model for rapid, integrated solution deployment.
The Regional Imperative: Addressing Latency in Latin American Theranostics
Latin America significantly lags global leaders in nuclear medicine and theranostics, facing systemic challenges in infrastructure, expertise, and adoption of advanced modalities. A critical deficit in cyclotrons and radiopharmaceutical production hinders patient access to cutting-edge diagnostic and therapeutic options. This partnership directly addresses these regional gaps, establishing LaCardio as a pivotal center for the entire region's advancement.
The Clinical Imperative: Leading Latin America's Transition to Precision Medicine
LaCardio's position as a leader in cardiovascular medicine, transplants, and complex pediatrics creates the perfect foundation to lead the region's adoption of theranostics—the revolutionary fusion of diagnostics and targeted therapy.
In Colombia, where cardiovascular disease remains the leading cause of death, the evolution from anatomical imaging to the "see it, treat it" paradigm represents both a clinical necessity and a public health mandate.
Current imaging modalities provide an incomplete picture. The true power of advanced PET imaging lies in its ability to move beyond anatomy and illuminate the underlying biology of disease, providing the diagnostic foundation for targeted radiopharmaceutical therapies.
1
Gold Standard Cardiac Imaging
PET with Nitrogen-13 Ammonia offers superior image quality, lower radiation exposure, and the unique ability to quantify coronary flow reserve for more accurate diagnosis and risk stratification.
2
Advanced Cardiac Diagnostics
Nuclear scintigraphy provides definitive non-invasive diagnosis for cardiac amyloidosis, present in up to 19% of certain heart failure patient groups.
3
Personalized Treatment Guidance
FDG-PET detects active myocardial inflammation, guiding immunosuppressive therapy and monitoring treatment response for myocarditis and inflammatory cardiomyopathy.
The Knowledge Transfer Advantage: A Proven Blueprint for Success
The decision to establish an in-house radiopharmacy and theranostics program extends far beyond the acquisition of equipment. It requires world-class expertise in facility design, regulatory compliance, radiochemistry, quality assurance, and clinical protocol development.
Traditional equipment vendors offer transactional relationships, leaving hospitals to navigate these complexities alone—a primary cause of project delays, budget overruns, and underutilization in Latin America.
NucleoPROJ
Strategic advisory services covering business model development, financial planning, facility design, and comprehensive regulatory strategy with INVIMA and Ministerio de Minas y Energía.
NucleoLAB & NucleoSITE
Complete technology package featuring the IONETIX ION-12SC cyclotron with innovative modular shielding, eliminating the need for multi-year concrete bunker construction.
NucleoPHARM
Delivery and commissioning of a complete, cGMP-compliant radiopharmacy with shielded hot cells, automated synthesis modules, and a fully equipped quality control laboratory.
NucleoRAD & NucleoEDU
Comprehensive radiation safety program with advanced monitoring systems plus multi-stage training and certification program for all key personnel.
This holistic, partnership-based MSO model is what distinguishes our approach. While a conventional vendor provides a tool, we provide the complete blueprint, training, and long-term support to build a world-class theranostics program.
The HIC Case Study: Unprecedented ROI in the Colombian Healthcare Context
The most compelling evidence for the value of this partnership model is not theoretical, but a tangible success story achieved here in Colombia. The transformation of the Hospital Internacional de Colombia (HIC) into a leading theranostics center provides a clear and quantifiable blueprint for success within the same national environment.
220
Days to Implementation
Compared to 2-4 years with conventional approaches
$3.4M
Total Investment
Versus $17.5M+ for traditional installation methods
$11.6M
Avoided Opportunity Cost
Revenue that would have been foregone during typical construction delays
4.2
Year Payback Period
Compared to >10 years for conventional installations (if achieved)
The 220-day implementation timeline is not merely an operational efficiency; it is a strategic advantage that allows LaCardio to seize first-mover status, establish referral patterns for advanced theranostics, and begin generating returns almost immediately.
Technological Superiority: The Engine of Theranostic Leadership
At the heart of our solution is the IONETIX ION-12SC cyclotron, representing a generational leap in radiopharmaceutical production. Born from groundbreaking research at MIT, this is the world's first and most advanced commercial compact superconducting cyclotron.
For LaCardio's technical leadership, the practical implications of this design are substantial. Its superconducting magnet technology enables a system that is drastically smaller, lighter, and more energy-efficient—making on-site production more accessible and affordable than ever before.
The system reliably produces the full range of key PET isotopes on-demand:
  • Fluorine-18 (¹⁸F) FDG: The foundational workhorse of PET imaging
  • Nitrogen-13 (¹³N) Ammonia: The gold standard for cardiac perfusion imaging
  • Gallium-68 (⁶⁸Ga): Critical for next-generation diagnostics
  • Copper-64 (⁶⁴Cu): Advanced research capabilities for novel applications
89%
Size Reduction
The ION-12SC weighs just 2.3 tons vs. 20+ tons for conventional systems
58%
Energy Savings
Consumes <34 kW vs. 75-80 kW for traditional cyclotrons
1/3
Staffing Requirements
Requires just 1 certified operator vs. 2-5 specialists for conventional systems
A Bespoke Vision: LaCardio as Latin America's Theranostics Leader
The true value of this partnership lies not in the hardware, but in the institutional identity it empowers LaCardio to build. This investment will accelerate LaCardio's tripartite mission of world-class clinical care, pioneering research, and profound social impact.
1
2
3
4
5
1
Regional Theranostics Leadership
Establishing LaCardio as the undisputed center of excellence for all of Latin America
2
Preeminent Clinical Theranostics
On-site production of N-13 Ammonia combined with proprietary MyoFlow™ quantitative analysis software creates a diagnostic service that is clinically superior and logistically unmatched
3
Epicenter of Research
Positioning LaCardio as the premier global site in Latin America for radiopharmaceutical clinical trials, unlocking significant new revenue streams from pharmaceutical sponsors investing billions in Radioligand Therapy (RLT)
4
Leading Cardio-Oncology Program
Creating an immediate opportunity to launch a comprehensive Cardio-Oncology program built on theranostic principles, addressing the growing concern of cancer therapy cardiotoxicity
5
Expanded Social Mission
By becoming a regional production hub for advanced radiopharmaceuticals at lower cost, LaCardio can increase the accessibility of these critical treatments, extending precision medicine to a wider population
The Partnership Framework: A Clear Path Forward
Our partnership framework provides LaCardio with a clear and certain path from decision to delivery of its regional theranostics center. This framework eliminates the uncertainty and open-ended risk that characterize conventional capital projects.
1
Months 1-2: Foundation & Regulatory
Finalization of technical dossier for INVIMA submission while LaCardio's team, with our guidance, commences site preparation
2
Months 2-6: Manufacturing & Site Prep
Production of the ION-12SC cyclotron and all radiopharmacy components while minimal site adaptations are completed at LaCardio
3
Months 6-7: Logistics & Installation
Complete management of the logistical chain from international transport to on-site assembly of the modular shielding system
4
Month 8: Commissioning & Training
Full system calibration, validation, and intensive on-site NucleoEDU training program, certifying LaCardio's staff for independent operation
The total investment for this complete, turnkey solution is $3,395,000 USD—a fixed, predictable cost that includes all equipment, project management, installation, commissioning, and training. Financial projections indicate the investment will be paid back within the second year of operation.
A Strategic Choice for Generational Excellence: Partnering with Synapse LATAM
Synapse LATAM represents a timely and strategic opportunity to transform molecular imaging and targeted therapy across Latin America. As a joint venture between Nucleotron MIT and bioaccess®, we bring a proven U.S. model, anchored by the success of CIRA Health, to enable Latin American healthcare systems to lead in the burgeoning field of Theranostics.
Proven U.S. Model
Replicating CIRA Health's success for robust theranostic and clinical research infrastructure.
Advanced Capabilities
Enabling comprehensive Theranostic program development and molecular imaging excellence.
Regional Focus
Addressing the untapped Latin American market with tailored, localized solutions and expertise.
Our mission is to unlock access to life-changing diagnostic and therapeutic options for patients, establishing Latin America as a key player in the global Theranostics revolution.
A Strategic Choice for Generational Excellence
The decision before LaCardio is not a choice between two pieces of equipment, but a strategic choice between two distinct futures.
The conventional path involves a 2-4 year, high-risk construction project with unpredictable costs and uncertain outcomes. It carries immense project management burdens, significant disruption to the hospital's core mission, and a guaranteed multi-million-dollar opportunity cost.
The Synapse Latam partnership offers a rapid, 220-day, de-risked journey to becoming the undisputed theranostics leader in Latin America. It delivers immediate access to gold-standard diagnostics, creates a powerful engine for research, and unlocks a new revenue stream through clinical trials.
This partnership represents the most direct, effective, and strategically sound means for LaCardio to realize its vision of being the "hospital of the future" and to cement its legacy as the institution that brought personalized medicine to Latin America.

Long-Term Partnership & Support
Our "Elite" Service Contract includes:
  • 95% Minimum Uptime Guarantee
  • 24-Hour Emergency Response
  • 15-Year Parts Guarantee
This ensures LaCardio will not only achieve but sustain its position as the leading theranostics center in Latin America.
Synapse Latam is the commercial name of Synapse Global Theranostics Inc., a Delaware corporation with principal address at 2125 Biscayne Blvd., Suite 3 -2030, Miami, FL 33137